Cancer is a Growing Worldwide Problem

Billions of dollars have been spent on developing new cancer therapies. And yet, there have been limited advancements in treatment and healthcare costs continue to rise.

A collage of cancer patients and cancer ribbons.

Low Risk Investment Opportunity

  • ST-001 nanoFenretinide, our first, patented drug candidate, represents a vast $5 Billion+ market potential.
  • ST-001 is based upon the safe drug fenretinide which is broadly applicable to several cancer types and will be an affordable treatment option.
  • ST-001 has a clear regulatory path with a streamlined clinical trial plan with a relatively quick path to commercialization.
  • ST-001’s product development and manufacturing scale-up has been successfully completed.
  • We have the support of powerful institutions such as the National Cancer Institute (NCI) that is supplying fenretinide at no cost for our initial clinical trials.
  • SciTech has several exit options and expansion strategies.
A chemist at work in a laboratory.
Scientists examining an image from an electron microscope.

How We're Different

  • SciTech offers new hope to cancer patients by developing innovative, affordable, breakthrough drugs.
  • Our discoveries are rooted in well studied science for the development of new drugs for multiple cancers and other diseases.
  • Respect for patient lifestyle, needs and treatment options are at the core of what we do.
  • SciTech’s leadership and scientific advisory team consists of passionate and motivated industry executives with multiple successful exits that have the experience to bring disruptive drugs to market.

ST-001: A Cancer Breakthrough

  • ST-001 nanoFenretinide, our lead drug candidate, is patented and clinical trial ready for the treatment of T-cell non-Hodgkin’s lymphoma.
  • ST-001 may have potential use as an add-on therapy for existing cancer treatments, thereby minimizing the risk of recurrence, spreading or metastasizing.
Test tubes, beakers, and a model of an element on a table.
Arrows hitting a bullseye.

Our Strategy

  • Our accelerated trial plan for ST-001 provides a rapid path to commercialization and revenue generation.
  • We seek companies that want to expand their existing drug portfolio in oncology, or target new diseases, or develop combination drug therapies.
  • SciTech has enormous potential for multiple exit strategies as new drug candidates are developed with SDP.
  • Potential exit strategies include licensing deals or partnerships with other companies, a targeted acquisition, or go public.

Significant Milestones Achieved

Graphic representation of SciTech hitting development milestones.

SciTech has made great strides over the last several years in our quest to bring ST-001 to market.

  • U.S. Small Business Innovation Research (SBIR) grants from the National Cancer Institute.
  • Investigational New Drug (IND) approval from the FDA, required to start clinical trials.
  • FDA guided clinical trial plan: Accelerated time to market and revenue generation.
  • FDA Orphan Drug Designation: Providing SciTech with exclusive marketing and development rights, federal tax credits and FDA fee reductions.
  • Institutional Review Board (IRB) Approval: Initial clinical trial can begin at Rush University Medical Center in Chicago, IL.

The Market Opportunity

  • The immediate target market for ST-001 is estimated to be about $2 Billion for T-Cell Lymphomas and small cell lung cancer (SCLC).
  • Expanding SciTech’s pipeline by using our Delivery Platform greatly enhances our global market potential, estimated at $5B-25B+.
SciTech's immediate and long-term market opportunity.